Ainos, Inc. (AIMD) 10-Year Financial Performance & Capital Metrics

AIMD • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutAinos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.Show more

Revenue $21K -83.0%
EBITDA -$9M -8.4%
Net Income -$15M -7.9%
EPS (Diluted) -1.56 +53.6%
Gross Margin -153.73% +26.0%
EBITDA Margin -43607.93% -538.9%
Operating Margin -66772.17% -517.4%
Net Margin -71702.26% -535.8%
ROE -74.38% -59.6%
ROIC -39.81% -25.7%
Debt/Equity 0.77 +217.0%
Interest Coverage -22.45 +75.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 12.1%
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y12.06%

3Y-67.33%

TTM178.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM7.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM-7482.25%

ROCE

10Y Avg-161.7%

5Y Avg-58.81%

3Y Avg-50.95%

Latest-50%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.98K	0	250.93K	77.72K	11.73K	16.56K	594.56K	3.52M	122.11K	20.73K
Revenue Growth %	-	-1%	-	-0.69%	-0.85%	0.41%	34.9%	4.92%	-0.97%	-0.83%
Cost of Goods Sold+	19.77K	25.96K	60.32K	64.88K	8.77K	11.28K	184.18K	2.11M	375.85K	52.59K
COGS % of Revenue	10.01%	-	0.24%	0.83%	0.75%	0.68%	0.31%	0.6%	3.08%	2.54%
Gross Profit+	-17.8K	-25.96K	190.61K	12.85K	2.96K	5.29K	410.38K	1.41M	-253.73K	-31.87K
Gross Margin %	-9.01%	-	0.76%	0.17%	0.25%	0.32%	0.69%	0.4%	-2.08%	-1.54%
Gross Profit Growth %	-	-0.46%	8.34%	-0.93%	-0.77%	0.79%	76.64%	2.42%	-1.18%	0.87%
Operating Expenses+	521.8K	667.11K	770.38K	1.35M	1.58M	1.45M	4.28M	15.38M	12.95M	13.81M
OpEx % of Revenue	264.2%	-	3.07%	17.34%	134.97%	87.29%	7.19%	4.37%	106.07%	666.18%
Selling, General & Admin	521.8K	667.11K	770.38K	1.31M	1.53M	1.45M	2.36M	8.54M	5.64M	5.4M
SG&A % of Revenue	264.2%	-	3.07%	16.92%	130.5%	87.26%	3.96%	2.43%	46.15%	260.28%
Research & Development	0	0	0	32.59K	52.51K	389	1.92M	6.85M	7.32M	8.41M
R&D % of Revenue	-	-	-	0.42%	4.48%	0.02%	3.23%	1.95%	59.92%	405.9%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-519.82K	-667.11K	-579.76K	-1.33M	-1.58M	-1.44M	-3.87M	-13.98M	-13.21M	-13.84M
Operating Margin %	-263.2%	-	-2.31%	-17.17%	-134.72%	-86.97%	-6.5%	-3.97%	-108.15%	-667.72%
Operating Income Growth %	0.17%	-0.28%	0.13%	-1.3%	-0.18%	0.09%	-1.68%	-2.61%	0.06%	-0.05%
EBITDA+	-500.05K	-641.15K	-539.77K	-1.28M	-1.56M	-1.43M	-1.82M	-9.16M	-8.34M	-9.04M
EBITDA Margin %	-253.19%	-	-2.15%	-16.45%	-132.83%	-86.08%	-3.07%	-2.6%	-68.26%	-436.08%
EBITDA Growth %	0.17%	-0.28%	0.16%	-1.37%	-0.22%	0.08%	-0.28%	-4.03%	0.09%	-0.08%
D&A (Non-Cash Add-back)	19.77K	25.96K	39.99K	56.19K	22.24K	14.7K	2.04M	4.81M	4.87M	4.8M
EBIT	-519.82K	-667.11K	-579.76K	-1.33M	-1.58M	-1.44M	-3.87M	-13.95M	-13.63M	-14.25M
Net Interest Income+	0	0	-37.61K	-3.96K	-885	-10.19K	-18.69K	-53.53K	-144.19K	-616.47K
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	2.05K	2.87K	37.61K	3.96K	885	10.19K	18.69K	53.53K	144.19K	616.47K
Other Income/Expense	-2.05K	-2.87K	-37.61K	-3.96K	-885	-10.19K	-5.09K	-30.48K	-563.35K	-1.02M
Pretax Income+	-521.87K	-669.98K	-617.38K	-1.34M	-1.58M	-1.45M	-3.87M	-14.01M	-13.77M	-14.86M
Pretax Margin %	-264.24%	-	-2.46%	-17.22%	-134.8%	-87.58%	-6.51%	-3.98%	-112.76%	-716.98%
Income Tax+	0	0	0	0	0	0	16.14K	0	800	800
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-521.87K	-669.98K	-617.38K	-1.34M	-1.58M	-1.45M	-3.89M	-14.01M	-13.77M	-14.86M
Net Margin %	-264.24%	-	-2.46%	-17.22%	-134.87%	-87.58%	-6.54%	-3.98%	-112.77%	-717.02%
Net Income Growth %	0.16%	-0.28%	0.08%	-1.17%	-0.18%	0.08%	-1.68%	-2.6%	0.02%	-0.08%
Net Income (Continuing)	-521.87K	-669.98K	-617.38K	-1.34M	-1.58M	-1.45M	-3.89M	-14.01M	-13.77M	-14.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.39	-0.50	-0.41	-0.56	-0.74	-2.69	-2.59	-5.14	-3.36	-1.56
EPS Growth %	0.53%	-0.28%	0.18%	-0.37%	-0.32%	-2.64%	0.04%	-0.98%	0.35%	0.54%
EPS (Basic)	-0.39	-0.50	-0.41	-0.56	-0.74	-2.69	-2.59	-5.14	-3.36	-1.56
Diluted Shares Outstanding	1.34M	1.34M	1.51M	2.38M	2.15M	543.08K	1.51M	2.73M	4.1M	9.5M
Basic Shares Outstanding	1.34M	1.34M	1.51M	2.38M	2.15M	543.08K	1.51M	2.73M	4.1M	9.5M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	39.29K	262.4K	2.08M	1.3M	445.29K	76.41K	2.22M	2.85M	2.47M	4.34M
Cash & Short-Term Investments	21.14K	134.13K	1.98M	1.28M	409.04K	22.25K	1.75M	1.85M	1.89M	3.89M
Cash Only	21.14K	134.13K	1.98M	1.28M	409.04K	22.25K	1.75M	1.85M	1.89M	3.89M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	-32.12K	0	0	201.55K	455	56
Days Sales Outstanding	-	-	-	-	-	-	-	20.9	1.36	0.99
Inventory	0	14.7K	22.67K	0	4.13K	3.02K	0	595.22K	167.59K	143.76K
Days Inventory Outstanding	-	206.72	137.16	-	171.89	97.88	-	102.76	162.76	997.64
Other Current Assets	18.15K	0	0	26.58K	32.12K	0	466.2K	195.79K	419.52K	301.08K
Total Non-Current Assets+	77.9K	200.28K	209.38K	160.47K	151.33K	183.88K	38.6M	34.26M	29.37M	24.48M
Property, Plant & Equipment	5.8K	44.21K	27K	14.01K	5.07K	3.25K	1.19M	1.38M	876.57K	559.64K
Fixed Asset Turnover	0.34x	-	9.29x	5.55x	2.31x	5.10x	0.50x	2.56x	0.14x	0.04x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	72.11K	156.06K	182.39K	146.46K	146.26K	180.63K	37.33M	32.81M	28.28M	23.75M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	-151.33K	0	87.57K	80.68K	208.83K	174.42K
Total Assets+	117.19K	462.68K	2.29M	1.46M	596.63K	260.29K	40.82M	37.11M	31.84M	28.82M
Asset Turnover	0.02x	-	0.11x	0.05x	0.02x	0.06x	0.01x	0.09x	0.00x	0.00x
Asset Growth %	-0.72%	2.95%	3.96%	-0.36%	-0.59%	-0.56%	155.83%	-0.09%	-0.14%	-0.09%
Total Current Liabilities+	589.24K	1.27M	1.82M	733.62K	753.31K	1.1M	30.59M	2.47M	1.34M	3.95M
Accounts Payable	58.55K	168.76K	159.3K	115.31K	208.73K	145.57K	0	0	0	0
Days Payables Outstanding	1.08K	2.37K	964	648.75	8.69K	4.71K	-	-	-	-
Short-Term Debt	384.56K	791.48K	886.48K	513.36K	444.58K	953K	3.59M	1.26M	42K	3M
Deferred Revenue (Current)	0	124.83K	0	0	0	0	0	0	112.56K	106.33K
Other Current Liabilities	144.43K	190.76K	777.26K	104.95K	100K	-145.57K	0	0	0	0
Current Ratio	0.07x	0.21x	1.14x	1.78x	0.59x	0.07x	0.07x	1.15x	1.85x	1.10x
Quick Ratio	0.07x	0.19x	1.13x	1.78x	0.59x	0.07x	0.07x	0.91x	1.72x	1.06x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	30.25K	8.1K	6.06M	9.35M
Long-Term Debt	0	0	0	0	0	0	0	0	5.92M	9M
Capital Lease Obligations	0	0	0	0	0	0	30.25K	8.1K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	135.83K	348.94K
Total Liabilities	589.24K	1.27M	1.82M	733.62K	753.31K	1.1M	30.63M	2.48M	7.39M	13.3M
Total Debt+	384.56K	791.48K	886.48K	513.36K	444.58K	953K	3.62M	1.27M	5.96M	12M
Net Debt	363.42K	657.36K	-1.09M	-763.3K	35.54K	930.76K	1.87M	-584.74K	4.08M	8.11M
Debt / Equity	-	-	1.88x	0.70x	-	-	0.36x	0.04x	0.24x	0.77x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-253.20x	-232.36x	-15.41x	-336.78x	-1785.78x	-141.39x	-206.94x	-261.10x	-91.59x	-22.45x
Total Equity+	-472.04K	-809.9K	470.8K	730.08K	-156.68K	-838.28K	10.2M	34.63M	24.45M	15.52M
Equity Growth %	-14.35%	-0.72%	1.58%	0.55%	-1.21%	-4.35%	13.16%	2.4%	-0.29%	-0.37%
Book Value per Share	-0.35	-0.60	0.31	0.31	-0.07	-1.54	6.75	12.70	5.97	1.63
Total Shareholders' Equity	-472.04K	-809.9K	470.8K	730.08K	-156.68K	-838.28K	10.2M	34.63M	24.45M	15.52M
Common Stock	201.45K	219.16K	231.56K	391.18K	405.16K	420.66K	96.25K	40.02K	46.78K	154.27K
Retained Earnings	-596.62K	-1.27M	-1.88M	-3.19M	-4.77M	-6.22M	-10.11M	-24.12M	-37.89M	-52.75M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-76.87K	0	0	0	0	0	5.8K	-201.65K	-268.85K	-409.53K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-366.41K	-520.81K	-542.7K	-1.01M	-909.48K	-499.55K	-1.25M	-3.04M	-4.69M	-5.81M
Operating CF Margin %	-185.53%	-	-2.16%	-12.98%	-77.53%	-30.16%	-2.1%	-0.86%	-38.45%	-280.2%
Operating CF Growth %	0.34%	-0.42%	-0.04%	-0.86%	0.1%	0.45%	-1.5%	-1.43%	-0.54%	-0.24%
Net Income	-521.87K	-669.98K	-617.38K	-1.34M	-1.58M	-1.45M	-3.89M	-14.01M	-13.77M	-14.86M
Depreciation & Amortization	19.77K	25.96K	39.99K	56.19K	22.24K	14.7K	2.04M	4.83M	4.85M	4.8M
Stock-Based Compensation	0	0	106.25K	100.37K	0	524.78K	150.29K	6.42M	1.11M	3.54M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	39.54K	66.61K	38.89K	27.77K	395.04K	0	2.22K	0	2.9M	672.96K
Working Capital Changes	135.69K	123.22K	-110.46K	145.12K	254.54K	411.6K	441.72K	-289.35K	189.8K	37.12K
Change in Receivables	0	-93.87K	31.8K	-502.01K	0	0	0	-201.55K	201.09K	399
Change in Inventory	0	-14.7K	-7.97K	22.67K	-4.13K	1.11K	3.02K	-595.22K	221.77K	23.84K
Change in Payables	-8.61K	106.95K	-9.46K	54.84K	261.67K	419.62K	794.17K	0	0	0
Cash from Investing+	-11.58K	-148.33K	-49.1K	-7.28K	-13.11K	-7.24K	-180.52K	-630.18K	-101.53K	-125.29K
Capital Expenditures	-11.58K	-148.33K	-49.1K	-7.28K	-13.11K	-7.24K	-143.79K	-633.82K	-92.98K	-21.33K
CapEx % of Revenue	5.86%	-	0.2%	0.09%	1.12%	0.44%	0.24%	0.18%	0.76%	1.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-4.5K	-100.64K	-49.1K	-2.37K	0	0	-36.73K	3.65K	-8.54K	-103.96K
Cash from Financing+	80.57K	782.13K	2.44M	254.98K	54.97K	120K	3.15M	3.85M	4.92M	8.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-34.28K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	80.57K	519.63K	2.2M	289.26K	0	0	64.75K	0	-390K	-97.5K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-377.99K	-669.14K	-591.8K	-1.02M	-922.58K	-506.79K	-1.39M	-3.67M	-4.79M	-5.83M
FCF Margin %	-191.39%	-	-2.36%	-13.08%	-78.64%	-30.6%	-2.34%	-1.04%	-39.21%	-281.23%
FCF Growth %	0.32%	-0.77%	0.12%	-0.72%	0.09%	0.45%	-1.75%	-1.64%	-0.3%	-0.22%
FCF per Share	-0.28	-0.50	-0.39	-0.43	-0.43	-0.93	-0.92	-1.35	-1.17	-0.61
FCF Conversion (FCF/Net Income)	0.70x	0.78x	0.88x	0.75x	0.57x	0.34x	0.32x	0.22x	0.34x	0.39x
Interest Paid	0	0	0	0	903	0	19.38K	43.25K	16.9K	21.67K
Taxes Paid	0	0	0	0	0	0	0	0	800	800

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-131.13%	-222.94%	-551.86%	-	-83.1%	-62.49%	-46.62%	-74.38%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-47.71%	-45.47%	-31.66%	-39.81%
Gross Margin	-901.11%	-	75.96%	16.53%	25.22%	31.91%	69.02%	39.93%	-207.79%	-153.73%
Net Margin	-26424%	-	-246.04%	-1722.3%	-13487.2%	-8758.21%	-654.04%	-397.96%	-11276.98%	-71702.26%
Debt / Equity	-	-	1.88x	0.70x	-	-	0.36x	0.04x	0.24x	0.77x
Interest Coverage	-253.20x	-232.36x	-15.41x	-336.78x	-1785.78x	-141.39x	-206.94x	-261.10x	-91.59x	-22.45x
FCF Conversion	0.70x	0.78x	0.88x	0.75x	0.57x	0.34x	0.32x	0.22x	0.34x	0.39x
Revenue Growth	-	-100%	-	-69.03%	-84.91%	41.19%	3489.71%	491.97%	-96.53%	-83.02%

Frequently Asked Questions

Growth & Financials

Ainos, Inc. (AIMD) reported $0.1M in revenue for fiscal year 2024. This represents a 94% increase from $0.1M in 2011.

Ainos, Inc. (AIMD) saw revenue decline by 83.0% over the past year.

Ainos, Inc. (AIMD) reported a net loss of $15.0M for fiscal year 2024.

Dividend & Returns

Ainos, Inc. (AIMD) has a return on equity (ROE) of -74.4%. Negative ROE indicates the company is unprofitable.

Ainos, Inc. (AIMD) had negative free cash flow of $4.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Ainos, Inc. (AIMD) 10-Year Financial Performance & Capital Metrics

AIMD • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

Revenue $21K -83.0%
EBITDA -$9M -8.4%
Net Income -$15M -7.9%
EPS (Diluted) -1.56 +53.6%
Gross Margin -153.73% +26.0%
EBITDA Margin -43607.93% -538.9%
Operating Margin -66772.17% -517.4%
Net Margin -71702.26% -535.8%
ROE -74.38% -59.6%
ROIC -39.81% -25.7%
Debt/Equity 0.77 +217.0%
Interest Coverage -22.45 +75.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 12.1%
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y12.06%

3Y-67.33%

TTM178.19%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM7.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM-7482.25%

ROCE

10Y Avg-161.7%

5Y Avg-58.81%

3Y Avg-50.95%

Latest-50%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.98K	0	250.93K	77.72K	11.73K	16.56K	594.56K	3.52M	122.11K	20.73K
Revenue Growth %	-	-1%	-	-0.69%	-0.85%	0.41%	34.9%	4.92%	-0.97%	-0.83%
Cost of Goods Sold+	19.77K	25.96K	60.32K	64.88K	8.77K	11.28K	184.18K	2.11M	375.85K	52.59K
COGS % of Revenue	10.01%	-	0.24%	0.83%	0.75%	0.68%	0.31%	0.6%	3.08%	2.54%
Gross Profit+	-17.8K	-25.96K	190.61K	12.85K	2.96K	5.29K	410.38K	1.41M	-253.73K	-31.87K
Gross Margin %	-9.01%	-	0.76%	0.17%	0.25%	0.32%	0.69%	0.4%	-2.08%	-1.54%
Gross Profit Growth %	-	-0.46%	8.34%	-0.93%	-0.77%	0.79%	76.64%	2.42%	-1.18%	0.87%
Operating Expenses+	521.8K	667.11K	770.38K	1.35M	1.58M	1.45M	4.28M	15.38M	12.95M	13.81M
OpEx % of Revenue	264.2%	-	3.07%	17.34%	134.97%	87.29%	7.19%	4.37%	106.07%	666.18%
Selling, General & Admin	521.8K	667.11K	770.38K	1.31M	1.53M	1.45M	2.36M	8.54M	5.64M	5.4M
SG&A % of Revenue	264.2%	-	3.07%	16.92%	130.5%	87.26%	3.96%	2.43%	46.15%	260.28%
Research & Development	0	0	0	32.59K	52.51K	389	1.92M	6.85M	7.32M	8.41M
R&D % of Revenue	-	-	-	0.42%	4.48%	0.02%	3.23%	1.95%	59.92%	405.9%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-519.82K	-667.11K	-579.76K	-1.33M	-1.58M	-1.44M	-3.87M	-13.98M	-13.21M	-13.84M
Operating Margin %	-263.2%	-	-2.31%	-17.17%	-134.72%	-86.97%	-6.5%	-3.97%	-108.15%	-667.72%
Operating Income Growth %	0.17%	-0.28%	0.13%	-1.3%	-0.18%	0.09%	-1.68%	-2.61%	0.06%	-0.05%
EBITDA+	-500.05K	-641.15K	-539.77K	-1.28M	-1.56M	-1.43M	-1.82M	-9.16M	-8.34M	-9.04M
EBITDA Margin %	-253.19%	-	-2.15%	-16.45%	-132.83%	-86.08%	-3.07%	-2.6%	-68.26%	-436.08%
EBITDA Growth %	0.17%	-0.28%	0.16%	-1.37%	-0.22%	0.08%	-0.28%	-4.03%	0.09%	-0.08%
D&A (Non-Cash Add-back)	19.77K	25.96K	39.99K	56.19K	22.24K	14.7K	2.04M	4.81M	4.87M	4.8M
EBIT	-519.82K	-667.11K	-579.76K	-1.33M	-1.58M	-1.44M	-3.87M	-13.95M	-13.63M	-14.25M
Net Interest Income+	0	0	-37.61K	-3.96K	-885	-10.19K	-18.69K	-53.53K	-144.19K	-616.47K
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	2.05K	2.87K	37.61K	3.96K	885	10.19K	18.69K	53.53K	144.19K	616.47K
Other Income/Expense	-2.05K	-2.87K	-37.61K	-3.96K	-885	-10.19K	-5.09K	-30.48K	-563.35K	-1.02M
Pretax Income+	-521.87K	-669.98K	-617.38K	-1.34M	-1.58M	-1.45M	-3.87M	-14.01M	-13.77M	-14.86M
Pretax Margin %	-264.24%	-	-2.46%	-17.22%	-134.8%	-87.58%	-6.51%	-3.98%	-112.76%	-716.98%
Income Tax+	0	0	0	0	0	0	16.14K	0	800	800
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-521.87K	-669.98K	-617.38K	-1.34M	-1.58M	-1.45M	-3.89M	-14.01M	-13.77M	-14.86M
Net Margin %	-264.24%	-	-2.46%	-17.22%	-134.87%	-87.58%	-6.54%	-3.98%	-112.77%	-717.02%
Net Income Growth %	0.16%	-0.28%	0.08%	-1.17%	-0.18%	0.08%	-1.68%	-2.6%	0.02%	-0.08%
Net Income (Continuing)	-521.87K	-669.98K	-617.38K	-1.34M	-1.58M	-1.45M	-3.89M	-14.01M	-13.77M	-14.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.39	-0.50	-0.41	-0.56	-0.74	-2.69	-2.59	-5.14	-3.36	-1.56
EPS Growth %	0.53%	-0.28%	0.18%	-0.37%	-0.32%	-2.64%	0.04%	-0.98%	0.35%	0.54%
EPS (Basic)	-0.39	-0.50	-0.41	-0.56	-0.74	-2.69	-2.59	-5.14	-3.36	-1.56
Diluted Shares Outstanding	1.34M	1.34M	1.51M	2.38M	2.15M	543.08K	1.51M	2.73M	4.1M	9.5M
Basic Shares Outstanding	1.34M	1.34M	1.51M	2.38M	2.15M	543.08K	1.51M	2.73M	4.1M	9.5M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	39.29K	262.4K	2.08M	1.3M	445.29K	76.41K	2.22M	2.85M	2.47M	4.34M
Cash & Short-Term Investments	21.14K	134.13K	1.98M	1.28M	409.04K	22.25K	1.75M	1.85M	1.89M	3.89M
Cash Only	21.14K	134.13K	1.98M	1.28M	409.04K	22.25K	1.75M	1.85M	1.89M	3.89M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	-32.12K	0	0	201.55K	455	56
Days Sales Outstanding	-	-	-	-	-	-	-	20.9	1.36	0.99
Inventory	0	14.7K	22.67K	0	4.13K	3.02K	0	595.22K	167.59K	143.76K
Days Inventory Outstanding	-	206.72	137.16	-	171.89	97.88	-	102.76	162.76	997.64
Other Current Assets	18.15K	0	0	26.58K	32.12K	0	466.2K	195.79K	419.52K	301.08K
Total Non-Current Assets+	77.9K	200.28K	209.38K	160.47K	151.33K	183.88K	38.6M	34.26M	29.37M	24.48M
Property, Plant & Equipment	5.8K	44.21K	27K	14.01K	5.07K	3.25K	1.19M	1.38M	876.57K	559.64K
Fixed Asset Turnover	0.34x	-	9.29x	5.55x	2.31x	5.10x	0.50x	2.56x	0.14x	0.04x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	72.11K	156.06K	182.39K	146.46K	146.26K	180.63K	37.33M	32.81M	28.28M	23.75M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	-151.33K	0	87.57K	80.68K	208.83K	174.42K
Total Assets+	117.19K	462.68K	2.29M	1.46M	596.63K	260.29K	40.82M	37.11M	31.84M	28.82M
Asset Turnover	0.02x	-	0.11x	0.05x	0.02x	0.06x	0.01x	0.09x	0.00x	0.00x
Asset Growth %	-0.72%	2.95%	3.96%	-0.36%	-0.59%	-0.56%	155.83%	-0.09%	-0.14%	-0.09%
Total Current Liabilities+	589.24K	1.27M	1.82M	733.62K	753.31K	1.1M	30.59M	2.47M	1.34M	3.95M
Accounts Payable	58.55K	168.76K	159.3K	115.31K	208.73K	145.57K	0	0	0	0
Days Payables Outstanding	1.08K	2.37K	964	648.75	8.69K	4.71K	-	-	-	-
Short-Term Debt	384.56K	791.48K	886.48K	513.36K	444.58K	953K	3.59M	1.26M	42K	3M
Deferred Revenue (Current)	0	124.83K	0	0	0	0	0	0	112.56K	106.33K
Other Current Liabilities	144.43K	190.76K	777.26K	104.95K	100K	-145.57K	0	0	0	0
Current Ratio	0.07x	0.21x	1.14x	1.78x	0.59x	0.07x	0.07x	1.15x	1.85x	1.10x
Quick Ratio	0.07x	0.19x	1.13x	1.78x	0.59x	0.07x	0.07x	0.91x	1.72x	1.06x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	30.25K	8.1K	6.06M	9.35M
Long-Term Debt	0	0	0	0	0	0	0	0	5.92M	9M
Capital Lease Obligations	0	0	0	0	0	0	30.25K	8.1K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	135.83K	348.94K
Total Liabilities	589.24K	1.27M	1.82M	733.62K	753.31K	1.1M	30.63M	2.48M	7.39M	13.3M
Total Debt+	384.56K	791.48K	886.48K	513.36K	444.58K	953K	3.62M	1.27M	5.96M	12M
Net Debt	363.42K	657.36K	-1.09M	-763.3K	35.54K	930.76K	1.87M	-584.74K	4.08M	8.11M
Debt / Equity	-	-	1.88x	0.70x	-	-	0.36x	0.04x	0.24x	0.77x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-253.20x	-232.36x	-15.41x	-336.78x	-1785.78x	-141.39x	-206.94x	-261.10x	-91.59x	-22.45x
Total Equity+	-472.04K	-809.9K	470.8K	730.08K	-156.68K	-838.28K	10.2M	34.63M	24.45M	15.52M
Equity Growth %	-14.35%	-0.72%	1.58%	0.55%	-1.21%	-4.35%	13.16%	2.4%	-0.29%	-0.37%
Book Value per Share	-0.35	-0.60	0.31	0.31	-0.07	-1.54	6.75	12.70	5.97	1.63
Total Shareholders' Equity	-472.04K	-809.9K	470.8K	730.08K	-156.68K	-838.28K	10.2M	34.63M	24.45M	15.52M
Common Stock	201.45K	219.16K	231.56K	391.18K	405.16K	420.66K	96.25K	40.02K	46.78K	154.27K
Retained Earnings	-596.62K	-1.27M	-1.88M	-3.19M	-4.77M	-6.22M	-10.11M	-24.12M	-37.89M	-52.75M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-76.87K	0	0	0	0	0	5.8K	-201.65K	-268.85K	-409.53K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-366.41K	-520.81K	-542.7K	-1.01M	-909.48K	-499.55K	-1.25M	-3.04M	-4.69M	-5.81M
Operating CF Margin %	-185.53%	-	-2.16%	-12.98%	-77.53%	-30.16%	-2.1%	-0.86%	-38.45%	-280.2%
Operating CF Growth %	0.34%	-0.42%	-0.04%	-0.86%	0.1%	0.45%	-1.5%	-1.43%	-0.54%	-0.24%
Net Income	-521.87K	-669.98K	-617.38K	-1.34M	-1.58M	-1.45M	-3.89M	-14.01M	-13.77M	-14.86M
Depreciation & Amortization	19.77K	25.96K	39.99K	56.19K	22.24K	14.7K	2.04M	4.83M	4.85M	4.8M
Stock-Based Compensation	0	0	106.25K	100.37K	0	524.78K	150.29K	6.42M	1.11M	3.54M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	39.54K	66.61K	38.89K	27.77K	395.04K	0	2.22K	0	2.9M	672.96K
Working Capital Changes	135.69K	123.22K	-110.46K	145.12K	254.54K	411.6K	441.72K	-289.35K	189.8K	37.12K
Change in Receivables	0	-93.87K	31.8K	-502.01K	0	0	0	-201.55K	201.09K	399
Change in Inventory	0	-14.7K	-7.97K	22.67K	-4.13K	1.11K	3.02K	-595.22K	221.77K	23.84K
Change in Payables	-8.61K	106.95K	-9.46K	54.84K	261.67K	419.62K	794.17K	0	0	0
Cash from Investing+	-11.58K	-148.33K	-49.1K	-7.28K	-13.11K	-7.24K	-180.52K	-630.18K	-101.53K	-125.29K
Capital Expenditures	-11.58K	-148.33K	-49.1K	-7.28K	-13.11K	-7.24K	-143.79K	-633.82K	-92.98K	-21.33K
CapEx % of Revenue	5.86%	-	0.2%	0.09%	1.12%	0.44%	0.24%	0.18%	0.76%	1.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-4.5K	-100.64K	-49.1K	-2.37K	0	0	-36.73K	3.65K	-8.54K	-103.96K
Cash from Financing+	80.57K	782.13K	2.44M	254.98K	54.97K	120K	3.15M	3.85M	4.92M	8.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-34.28K	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	80.57K	519.63K	2.2M	289.26K	0	0	64.75K	0	-390K	-97.5K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-377.99K	-669.14K	-591.8K	-1.02M	-922.58K	-506.79K	-1.39M	-3.67M	-4.79M	-5.83M
FCF Margin %	-191.39%	-	-2.36%	-13.08%	-78.64%	-30.6%	-2.34%	-1.04%	-39.21%	-281.23%
FCF Growth %	0.32%	-0.77%	0.12%	-0.72%	0.09%	0.45%	-1.75%	-1.64%	-0.3%	-0.22%
FCF per Share	-0.28	-0.50	-0.39	-0.43	-0.43	-0.93	-0.92	-1.35	-1.17	-0.61
FCF Conversion (FCF/Net Income)	0.70x	0.78x	0.88x	0.75x	0.57x	0.34x	0.32x	0.22x	0.34x	0.39x
Interest Paid	0	0	0	0	903	0	19.38K	43.25K	16.9K	21.67K
Taxes Paid	0	0	0	0	0	0	0	0	800	800

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-131.13%	-222.94%	-551.86%	-	-83.1%	-62.49%	-46.62%	-74.38%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-47.71%	-45.47%	-31.66%	-39.81%
Gross Margin	-901.11%	-	75.96%	16.53%	25.22%	31.91%	69.02%	39.93%	-207.79%	-153.73%
Net Margin	-26424%	-	-246.04%	-1722.3%	-13487.2%	-8758.21%	-654.04%	-397.96%	-11276.98%	-71702.26%
Debt / Equity	-	-	1.88x	0.70x	-	-	0.36x	0.04x	0.24x	0.77x
Interest Coverage	-253.20x	-232.36x	-15.41x	-336.78x	-1785.78x	-141.39x	-206.94x	-261.10x	-91.59x	-22.45x
FCF Conversion	0.70x	0.78x	0.88x	0.75x	0.57x	0.34x	0.32x	0.22x	0.34x	0.39x
Revenue Growth	-	-100%	-	-69.03%	-84.91%	41.19%	3489.71%	491.97%	-96.53%	-83.02%

Frequently Asked Questions

Growth & Financials

Ainos, Inc. (AIMD) reported $0.1M in revenue for fiscal year 2024. This represents a 94% increase from $0.1M in 2011.

Ainos, Inc. (AIMD) saw revenue decline by 83.0% over the past year.

Ainos, Inc. (AIMD) reported a net loss of $15.0M for fiscal year 2024.

Dividend & Returns

Ainos, Inc. (AIMD) has a return on equity (ROE) of -74.4%. Negative ROE indicates the company is unprofitable.

Ainos, Inc. (AIMD) had negative free cash flow of $4.7M in fiscal year 2024, likely due to heavy capital investments.